DK0399666T3 - Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin - Google Patents

Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin

Info

Publication number
DK0399666T3
DK0399666T3 DK90304575.5T DK90304575T DK0399666T3 DK 0399666 T3 DK0399666 T3 DK 0399666T3 DK 90304575 T DK90304575 T DK 90304575T DK 0399666 T3 DK0399666 T3 DK 0399666T3
Authority
DK
Denmark
Prior art keywords
fusion proteins
serum albumin
human serum
proteins containing
terminal fragments
Prior art date
Application number
DK90304575.5T
Other languages
English (en)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of DK0399666T3 publication Critical patent/DK0399666T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90304575.5T 1989-04-29 1990-04-26 Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin DK0399666T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides

Publications (1)

Publication Number Publication Date
DK0399666T3 true DK0399666T3 (da) 1993-08-30

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90304575.5T DK0399666T3 (da) 1989-04-29 1990-04-26 Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin

Country Status (7)

Country Link
EP (2) EP0407008A3 (da)
AT (1) ATE92107T1 (da)
DE (1) DE69002395T2 (da)
DK (1) DK0399666T3 (da)
ES (1) ES2060033T3 (da)
GB (1) GB8909919D0 (da)
WO (1) WO1990013306A2 (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0428266B1 (en) * 1989-10-13 1994-09-28 Takara Shuzo Co. Ltd. Anticancer agent
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1322667A4 (en) * 2000-08-25 2004-08-18 Human Genome Sciences Inc TUMOR NECROSE FACTOR RECEPTORS 6-ALPHA AND 6-BETA
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
EP1948271B1 (en) 2005-11-17 2013-10-02 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
US20110118189A1 (en) 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
MX2011008799A (es) 2009-02-19 2011-09-27 Glaxo Group Ltd Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
AR078763A1 (es) 2009-10-27 2011-11-30 Glaxo Group Ltd Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX375112B (es) 2010-07-09 2025-03-06 Biogen Hemophilia Inc Polipéptidos de factor ix y métodos para usarlos.
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
PE20220401A1 (es) 2019-09-06 2022-03-22 Novartis Ag Proteinas de fusion terapeuticas
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
CN116574173B (zh) * 2023-06-25 2026-04-17 浙江诸暨聚源生物技术有限公司 蛋白稳定性增强的重组人源纤连蛋白突变体及其表达菌株
US20260167709A1 (en) 2024-09-11 2026-06-18 Novartis Ag Antibodies targeting il-31
US20260217815A1 (en) 2025-01-29 2026-07-30 Novartis Ag Treatment of atopic dermatitis with multispecific antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989004172A1 (en) * 1987-11-09 1989-05-18 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0407008A3 (en) 1991-07-17
GB8909919D0 (en) 1989-06-14
ATE92107T1 (de) 1993-08-15
WO1990013306A3 (en) 1991-05-02
EP0399666A1 (en) 1990-11-28
WO1990013306A2 (en) 1990-11-15
DE69002395T2 (de) 1993-11-25
DE69002395D1 (de) 1993-09-02
ES2060033T3 (es) 1994-11-16
EP0407008A2 (en) 1991-01-09
EP0399666B1 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DK0502956T3 (da) Fremstilling af en rekombinant human interleukin-1-inhibitor.
DE69228701D1 (de) Fragmente von Prion Proteinen.
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
ES2075155T3 (es) Separacion enzimatica de una secuencia de una proteina con amino terminal.
DE69309044D1 (de) Behandlung von asthma
NO923737D0 (no) Forbedret vevs-lim fremstilt ved anvendelse av kryopresipitat
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
NO883834D0 (no) Fremgangsmaate for fremstilling av nye hiv-proteiner og peptider.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
NO894949D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme benzopyranylpyrrolinonderivater.
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
SE9000793D0 (sv) Sdk-peptider,foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande dem
EP0326013A3 (en) Novel proteins derived from human alpha2-plasmin inhibitor or proteins similar thereto
DE69002383D1 (de) Zusammensetzung zur heilung von autoimmunkrankheiten.